German BioNTech has announced plans to market the world's first cancer vaccines. Obtaining a license for such drugs is expected in 2026. This was announced by BioNTech co-founders Ozlem Tureci and Ugur Sahin.
“We expect that our first cancer vaccines will be licensed by 2026 and go on sale. We currently have an antibody against a specific type of lung cancer and a candidate antibody against metastatic breast cancer,” Shaheen told Haber Global.
According to him, research is still ongoing on other developments that are expected to be effective in preventing other types of cancer, including skin, colon, uterine, prostate and lung cancer. Some of the studies have been extremely successful, and a vaccine is being developed. The company's goal is to create a "broad portfolio of cancer treatments" by 2030.
These vaccines differ from chemotherapy in that they “teach” the immune system to independently destroy foci of the disease. “We are working to ensure that the body's own defense system can fight cancer. Thus, there will be no need for chemotherapy, which poisons the entire body,” Türeci explained.
https://pharmnewskz.com/
